来源:E药经理人不出意外,2025年全球制药营收TOP10格局又将巨变。图丨2024年前三季度全球制药营收TOP10首先是辉瑞,如果说今年上半年因为辉瑞两次公布成本削减计划和接连裁员,业界还在为其跌落神坛感到惋惜,到了第三季度,辉瑞就用单季度营收同比增长32%的实力证明,宇宙大药厂永远是宇宙大药厂。接着是礼来和诺和诺德,前者凭借315亿美元的前三季度营收,终究还是将GSK挤出了全球制药企业营收前十...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.